Evidence map›Paper›PMID 33302541›Full record

ReviewMolecules (Basel, Switzerland)2020

Comprehensive Review on Alzheimer's Disease: Causes and Treatment.

Zeinab Breijyeh, Rafik Karaman

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,248 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,248citing papers in PubMed, 9 pooled it
146.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1,248 citing papers in PubMed, 9 syntheses or guidelines pooled it, 2,526 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Evidence of the Efficacy of Acetylcholinesterase Inhibitors inCNS & neurological disorders drug targets · 2026
    Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Review
  13. Review
  14. Article
  15. Article
  16. Unveiling the pathogenesis and therapeutic strategies of Alzheimer's disease through cuproptosis.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026
    Review
  17. Review
  18. Review
  19. Transcriptomic Signatures of Microglial Phagocytosis Reveal Diagnostic Markers and Immune Landscape in Alzheimer's Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  20. Article

1,188 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Zeinab BreijyehPharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem 20002, Palestine.ORCID 0000-0003-1233-7826
Rafik KaramanPharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem 20002, Palestine.ORCID 0000-0001-5526-4490
Al-Quds University · PS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease. Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsBiomarkersDisease ManagementDisease SusceptibilityHumansNeurodegenerative DiseasesRisk AssessmentRisk FactorsSeverity of Illness Indextau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer’s diseasechaperonsdisease-modifying therapyheat shock proteinsneurodegenerationrisk factorstau proteinβ-amyloid peptide

Identifiers

PMID33302541
PMCPMC7764106
OpenAlexW3112948680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.